DOM-DIVALPROEX TABLET (ENTERIC-COATED)
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
21-06-2017
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
VALPROIC ACID (DIVALPROEX SODIUM)
Inapatikana kutoka:
DOMINION PHARMACAL
ATC kanuni:
N03AG01
INN (Jina la Kimataifa):
VALPROIC ACID
Kipimo:
125MG
Dawa fomu:
TABLET (ENTERIC-COATED)
Tungo:
VALPROIC ACID (DIVALPROEX SODIUM) 125MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
100/500
Dawa ya aina:
Prescription
Eneo la matibabu:
MISCELLANEOUS ANTICONVULSANTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0112996004; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2002-04-10
Tabia za bidhaa
PRODUCT MONOGRAPH
PR
DOM-DIVALPROEX
Divalproex Sodium Delayed-Release Tablets, USP
125 mg, 250 mg, 500 mg
ANTIEPILEPTIC
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
Date of Revision:
June 20, 2017
Submission Control No: 206234
_Dom-DIVALPROEX Product Monograph _
_Page 2 of 60_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................22
DRUG INTERACTIONS
..................................................................................................29
DOSAGE AND ADMINISTRATION
..............................................................................36
OVERDOSAGE
................................................................................................................39
ACTION AND CLINICAL PHARMACOLOGY
............................................................40
STORAGE AND STABILITY
..........................................................................................43
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................43
PART II: SCIENTIFIC INFORMATION
...............................................................................45
PHARMACEUTICAL INFORMATION
..........................................................................45
CLINICAL TRIALS
..........................................................................................................46
DETAILED PHARMACOLOGY
................................................
Soma hati kamili
